Why do highly sophisticated immunotherapies—such as Chimeric Antigen Receptor (CAR) T cells or immune checkpoint inhibitors—frequently fail when facing solid tumors? In hematological malignancies (blood cancers), engineered immune cells find their targets with relative ease. However, solid tumors like pancreatic ductal adenocarcinoma, glioblastoma, and ovarian cancer construct a highly sophisticated, multi-layered defensive ecosystem known as the immunosuppressive tumor microenvironment (TME).
As reviewed by Rui Zheng et al., this environment acts as both a physical fortress and a biochemical shield, actively neutralizing infiltrating immune cells and rendering standard therapies ineffective. To make immunotherapy work in solid tumors, researchers are shifting focus from simply enhancing T-cell targeting to actively dismantling and reprogramming the TME.
The Biochemical Shield: How Tumors Hijack and Recruit Suppressor Cells
The first layer of defense is cellular reprogramming. Instead of merely evading detection, solid tumors actively secrete chemokines and metabolic byproducts to recruit host immune cells and "brainwash" them into protecting the tumor. This turns an active immune response into an immunologically "cold" environment or an "immune desert."
For instance, in ovarian cancer, Baoyue Pan et al. demonstrated that the transcription factor MYBL2 directly drives the expression of the chemokine CCL2. This axis acts as a homing beacon for immunosuppressive macrophages, drawing them into the TME to form an immune shield that excludes cytotoxic T cells.
Similarly, metabolic alterations can reshape the local immune landscape. Landon J. Hansen et al. showed that the loss of the enzyme MTAP in glioblastoma leads to the accumulation of methylthioadenosine (MTA), a substrate that directly stimulates alternative, tumor-protective M2 macrophage polarization.
Beyond macrophages, tumors recruit myeloid-derived suppressor cells (MDSCs) to actively disarm any T cells that manage to penetrate. Zhewen Xiong identified that tumor-intrinsic PPARγ signaling in hepatocellular carcinoma is a primary driver of MDSC recruitment. These MDSCs directly shut down the cytolytic activity of T cells, preventing the immune system from eradicating malignant tissue even when checkpoint inhibitors are present.
[Tumor Signaling]
│
├─► MYBL2–CCL2 Axis ──► Recruits M2 Macrophages ──┐
├─► MTAP Loss (MTA) ──► Drives M2 Polarization ──┼─► [Immunosuppressive Shield]
└─► PPARγ Pathway ──► Recruits MDSCs ──┘
│
▼
Inhibits Cytotoxic T Cells
The Physical Wall: Extracellular Barriers and T-Cell Exclusion
Even if an immune cell resists these suppressive chemical signals, it faces a daunting physical barrier. The stroma of solid tumors is often dense, hypoxic, and cross-linked with extracellular matrix (ECM) components that physically restrict cell migration. If T cells cannot physically penetrate the dense stroma, they cannot kill the tumor.
A primary culprit in this structural exclusion is hyaluronic acid (HA), a major component of the ECM. To bypass this wall, Ruocong Zhao et al. engineered mesothelin-specific CAR-T cells to co-express and secrete a human hyaluronidase (sPH20). By equipping the T cells with the molecular equivalent of a machete, the engineered cells successfully degraded the HA matrix, allowing them to penetrate deep into gastric tumors and exert their anti-tumor functions.
Furthermore, abnormal tumor vasculature driven by vascular endothelial growth factor (VEGF) creates high interstitial fluid pressure and hypoxia, which induces functional exhaustion in infiltrating T cells. As noted by Yuan Meng et al., overcoming this requires a coordinated attack that normalizes blood vessels while simultaneously blocking inhibitory checkpoints like PD-L1.
Turning Cold Tumors Hot: Strategies for TME Reprogramming
Understanding why the TME is suppressive has unlocked several innovative strategies designed to "thaw" cold tumors and sensitize them to immunotherapy.
1. Disrupting Recruitment Axes
By targeting the upstream regulators of suppressive chemokines, researchers can prevent the shield from forming. For example, Baoyue Pan et al. demonstrated that inhibiting the upstream kinase CDK2 breaks the MYBL2–CCL2 axis, preventing macrophage-mediated resistance and sensitizing tumors to anti-PD-1 therapy.
2. Multi-Functional Viral Factories
Rather than relying on systemic drug delivery, researchers are using engineered oncolytic viruses to reshape the TME locally. The recombinant adenovirus developed by Yuan Meng et al. simultaneously lyses tumor cells, secretes anti-VEGF antibodies to repair abnormal vasculature, and utilizes shRNA to silence PD-L1 expression, effectively turning an immune desert into a zone of active lymphocyte infiltration.
3. Exploiting Inflammatory Cell Death
Another powerful approach is forcing tumor cells to die in a way that alerts the immune system. Boshu Ouyang et al. utilized an AI-driven platform to discover drug pairs that trigger pyroptosis—a highly inflammatory form of programmed cell death. The resulting cellular rupture releases a cascade of pro-inflammatory biofactors that reverse the cold phenotype, transforming a hostile microenvironment into one that actively recruits and activates adaptive immune cells.
By shifting the therapeutic paradigm from merely targeting the cancer cell to actively remodeling its surrounding ecosystem, these approaches offer a blueprint for unlocking the full potential of immunotherapy in solid tumors.